InVasc Therapeutics Awarded Two Phase 1 SBIR Grants

ATLANTA--(BUSINESS WIRE)--InVasc Therapeutics, Inc. today announced that it has been awarded two Small Business Innovations Research (SBIR) Phase 1 grants by the National Institutes of Health. One grant is to continue research and development of small molecule drugs for the prevention and treatment of hypertension and stroke based on derivatives of alpha lipoic acid. The second grant is to advance the discovery and development of inhibitors of myeloperoxidase for use in treating or preventing acute vascular or inflammatory events. The aggregate funding from these two Phase 1 grants is nearly $400,000.